Abivax stock down 26% over the quarter despite its rebound
The Paris-based biotech specialising in inflammatory diseases continues its rebound in mid-afternoon, in a Paris market that is slightly trending higher. This recovery follows several weeks of selling pressure, which have left the stock well below its medium-term benchmarks.
A stock that is back above its MM20 but remains far below its MM200
Abivax gains 1.93% to €81.85 while the SBF 120 rises 0.28%. The stock sits 2.62% above its MM20 (€79.76), extending the rebound of recent sessions. However, it remains below its MM50 (€84.80) and 16.58% under its MM200 (€98.12), a gap that illustrates the extent of the three-month decline (-26.33%).
The €76.05 support, broken on November 6, has since been recovered, while resistance lies at €87.80. The weekly gain of 3.28% is not enough to erase the quarterly decline.
Dual listing plays a role here: the ordinary share in Paris and the Nasdaq ADS trade at the same price in real time, the American market being the most liquid. The Nasdaq closed down 0.74% yesterday, with no visible effect on the stock.
Five funds hold a combined 5.59% of the capital sold short
On the positioning front, five funds remain net short on the stock, representing 5.59% of the capital according to the disclosures reviewed, the latest dated November 9. This combined position has risen by 0.24 points over thirty days (from 5.35% previously).
A level above 3% shows that some institutional investors remain positioned against the stock or are seeking to hedge an exposure, without their motivations being known.
The increase over one month is modest, which does not indicate an acceleration of the movement. As for price, the RSI at 52 is neutral, and the MACD, still negative at -1.35, is approaching its signal line with a positive histogram at 0.62.
The gap to the MM50, located 3.48% above the price, will be the next benchmark to watch during the session.
